Company intelligence / Profile preview

Peritech Pharma

Ownership
Private
Development stage
Other
01

Overview

Peritech Pharma’s lead product, PP-110—a novel over-the-counter anti-hemorrhoidal gel—demonstrated superior efficacy to Preparation-H in a pivotal clinical trial. The product has been commercialized in 24 countries. Another candidate, PP-120 for pruritus ani, completed Phase I testing and was planned for a pivotal study

Therapeutic areas
GastroenterologyDermatology
Modalities
Small moleculeGel-based drug delivery
Industry
Biotech

Beyond the preview

Go deeper on Peritech Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peritech Pharma.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call